Oscotec completes Phase I study for novel osteoporosis drug

Published: 2010-02-10 06:56:00

Updated: 2010-02-10 06:56:00

Oscotec Inc. says it has successfully completed Phase I clinical trial of a novel anti-bone resorbing small molecule “OCT-1547” in the Netherlands, to evaluate safety, tolerability and pharmacokinetics as an orally administered therapeutic agent for the treatment of osteoporosis.

OCT-1547 is unique in its action mechanism differentiating itself from existing bisphosphonate agents, according ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.